




RealRate

PHARMACEUTICAL 2019

Axsome Therapeutics Inc.
Rank 338 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2019

Axsome Therapeutics Inc. Rank 338 of 371

The relative strengths and weaknesses of Axsome Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Axsome Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 140% points. The greatest weakness of Axsome Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 420% points.

The company's Economic Capital Ratio, given in the ranking table, is -836%, being 505% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	15,215
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,822
Liabilities, Non-Current	3,619
Other Assets	112
Other Compr. Net Income	0
Other Expenses	-2,791
Other Liabilities	0
Other Net Income	-910
Property and Equipment	52
Research and Development	23,495
Revenues	0
Selling, General and Administrative Expense	9,352

Output Variable	Value in 1000 USD
Assets	15,379
Liabilities	14,441
Expenses	30,056
Stockholders Equity	938
Net Income	-30,965
Comprehensive Net Income	-30,965
Economic Capital Ratio	-836%

